In summary, this study is the first to demonstrate the protective effects of Srxn1 against TAC‐induced cardiac oxidative stress and inflammation, which are induced by the inhibited activation of the TLR4/NF‐κB signalling pathway. Here, SRXN1 is linked to persistent truncus arteriosus.